Trinity Biotech plc

Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.